<DOC>
	<DOCNO>NCT00486057</DOCNO>
	<brief_summary>The purpose study examine outcomes receive Daclizumab part immuno-suppression protocol follow heart transplantation . Literature suggest time first rejection episode avoid delay use induction therapy .</brief_summary>
	<brief_title>Daclizumab Experience Pediatric Heart Transplant</brief_title>
	<detailed_description>In August 2005 heart transplant team Children 's Healthcare Atlanta begin protocol Daclizumab 1mg/kg IV every two week 5 dos ; 1st dose receive operating room follow discontinuation cardiopulmonary bypass . Since one year pass follow initiation practice , necessary review immuno-suppression strategy determine , fact , clinical benefit reduce rejection without increase vulnerability immuno-compromised host . We wish review heart transplant recipient record August 1 , 2004 October 15 , 2006 . Historically , Children 's do approximately 10 transplant per year ; therefore , review approximately 15 chart Children 's Healthcare Atlanta Sibley Heart Center Cardiology .</detailed_description>
	<mesh_term>Daclizumab</mesh_term>
	<criteria>Status post heart transplant Age 021 year Received Daclizumab induction therapy Those meet inclusion criterion</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>21 Years</maximum_age>
	<verification_date>November 2007</verification_date>
	<keyword>Daclizumab</keyword>
	<keyword>Immuno-suppression protocol</keyword>
	<keyword>Heart Transplant</keyword>
	<keyword>Rejection</keyword>
</DOC>